Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.76 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7418001 | 0.92 | SLC18A3 (0.73) | HTR2ASLC18A3KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6344464 | 0.90 | HTR2A (0.73) | HTR2AHTR2CHTR2B | |
| SCHEMBL6154035 | 0.89 | HTR2A (0.69) | HTR2ASLC18A3HTR2CHTR2B | |
| SCHEMBL1582470 | 0.86 | HTR2A (0.87) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6209404 | 0.86 | HTR2A (0.66) | HTR2ACYP3A4CYP2D6SIGMAR1HTR2C | |
| SCHEMBL10963541 | 0.86 | KCNH2 (0.73) | HTR2AHTR2CHTR2B | |
| SCHEMBL6154064 | 0.86 | GAA (0.70) | HTR2ASLC18A3HTR2CHTR2B | |
| SCHEMBL6531855 | 0.86 | HTR2A (0.69) | HTR2ASLC18A3KDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7418228 | 0.85 | HTR2A (0.85) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5539621 | 0.85 | SIGMAR1 (0.65) | HTR2ASIGMAR1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133524-A1 | A PROCESS FOR SYNTHESIZING KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-101384581-B | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| CN-101384581-A | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | HTR2A, HTR2B, HTR2C | HTR2A 1/4885SLC18A3 513/4885KDM4E 4086/4885 |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | HTR2A 1/4885SLC18A3 332/4885KDM4E 1738/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | HTR2A 1/4885SLC18A3 332/4885KDM4E 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.